Dr Bill Nelson talks with three-time cancer survivor Kristina Baum about the challenges of confronting her disease and successfully running the New York City Marathon in November.
In the next Cancer Matters podcast, Dr Bill Nelson and Dr Ashani Weeraratna discuss how melanoma can arise through changes in our skin as we age.
Some days, when 37-year-old Kristina Baum laces up her running shoes and starts out on her daily training run, she says she feels like someone is taking a sledgehammer to her lungs. Other days, she feels fantastic. That’s really not too different from how other runners training for a marathon describe the ups and downs […]
Researchers Advance Role of Circulating Tumor DNA to Detect Early Melanoma Growth, Uncover Treatment Options
Researchers at the Johns Hopkins Kimmel Cancer Center say they have added to evidence that measuring and monitoring tumor DNA that naturally circulates in the blood of melanoma patients can not only reliably help reveal the early stages of cancer growth and spread but also uncover new treatment options that tumor genetic analysis alone may […]
This blog post was written by Kristina Baum, who has melanoma and is participating in a clinical trial on immunotherapy at the Johns Hopkins Kimmel Cancer Center. For more information on Kristina's story, watch her interview with Denise Grady on the New York Times' Facebook page or follow her on Twitter at @kristinabaum. For the post, […]
One-third of patients with metastatic melanoma treated with immunotherapy drug nivolumab survive five years
At the 2016 American Association for Cancer Research annual meeting today, scientists presented their results of a follow-up study tracking the survival of metastatic melanoma patients who were treated with the immunotherapy drug nivolumab. The drug is currently approved by the U.S. Food and Drug Administration for advanced lung and kidney cancers and advanced melanomas. […]
In today’s news, former President Jimmy Carter, who has metastatic melanoma, revealed that he has responded well to treatment. We asked melanoma expert Evan J. Lipson, M.D., for his thoughts: “I was pleased to hear President Carter’s report that his most recent MRI brain scan did not reveal any signs of the original cancer spots […]
This week, the FDA approved a new therapy called talimogene laherparepvec, which goes by the trade name, Imlygic, for the treatment of certain types of melanoma. Suzanne Topalian, M.D., professor of surgery and oncology, and director of the melanoma program at the Johns Hopkins Kimmel Cancer Center offered the following insights on the drug's approval: “This approval […]
Cancer headlines this past month included two studies on colonoscopy, a screening tool for colon cancer. The first study looks at the long-term benefits of colonoscopy and found that 50 percent of colon cancer cases were avoided by a single colonscopy. In the Cancer News Review podcast, William Nelson, M.D., Ph.D., director of the Johns Hopkins Kimmel Cancer […]
Researchers from the Vanderbilt-Ingram Cancer Center and other institutions reported more data today on studies of a new melanoma drug that target products of a cancer-causing mutation in the BRAF gene. The study, published in the New England Journal of Medicine, tracked patients with metastatic melanoma who have been followed for more than a year […]